Better Therapeutics, Inc. (BTTX) has 34 open-market insider trades by 10 insiders since 2021. The most active filer is Andrew J. Armanino, Director.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| David P. Perry 2015 Trust | 10% Owner | — | 3 | $10.9M | 2023-04-10 |
| David P. Perry | Chairman | — | 1 | $1.8M | 2024-02-09 |
| Geoffrey M. Parker | Dir | — | 5 | $1.8M | 2023-12-18 |
| Andrew J. Armanino | Dir | — | 7 | $1.4M | 2023-12-18 |
| Frank Karbe | CEO | — | 3 | $707K | 2023-12-18 |
| Mark Heinen | — | — | 5 | $186K | 2023-04-05 |
| Risa J. Lavizzo-mourey | Dir | — | 1 | $46K | 2023-12-18 |
| Mark A. Berman | Chief Medical Officer | — | 1 | $40K | 2023-12-18 |
| Elder Granger | Dir | — | 3 | $32K | 2023-12-18 |
| Kevin Appelbaum, or his successor(s), as Trustee of the Kevin Appelbaum Revocable Trust under Revocable Trust Declaration dated 5/16/2020, as amended | 10% | — | 5 | $26K | 2022-03-31 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Mark A. Berman | Chief Medical Officer | Buy | $40K | 2023-07-27 |
| Andrew J. Armanino | Director | Buy | $400K | 2023-07-27 |
| Elder Granger | Director | Buy | $25K | 2023-07-27 |
| Frank Karbe | CEO | Buy | $200K | 2023-07-27 |
| Geoffrey M. Parker | Director | Buy | $1.0M | 2023-07-27 |
| David P. Perry | Chairman | Buy | $1.8M | 2023-07-27 |
Companies that share insiders with BTTX, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| Elder Granger | Director | Buy | $522 | 2023-05-16 |
| Frank Karbe | — | Buy | $402K | 2023-04-10 |
| Geoffrey M. Parker | Director | Buy | $503K | 2023-04-10 |
| David P. Perry 2015 Trust | 10% Owner | Buy | $8.2M | 2023-04-10 |
| Frank Karbe | — | Buy | $105K | 2022-09-15 |
| David P. Perry 2015 Trust | 10% Owner | Buy | $184K | 2022-09-15 |
| Mark Heinen | — | Buy | $148K | 2022-09-12 |
| Mark Heinen | — | Buy | $4K | 2022-06-24 |
| Andrew J. Armanino | Director | Buy | $21K | 2022-06-14 |